HRP20120434T2 - Spojevi 4-oksadiazolil-piperidina i njihova uporaba - Google Patents
Spojevi 4-oksadiazolil-piperidina i njihova uporaba Download PDFInfo
- Publication number
- HRP20120434T2 HRP20120434T2 HRP20120434TT HRP20120434T HRP20120434T2 HR P20120434 T2 HRP20120434 T2 HR P20120434T2 HR P20120434T T HRP20120434T T HR P20120434TT HR P20120434 T HRP20120434 T HR P20120434T HR P20120434 T2 HRP20120434 T2 HR P20120434T2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound according
- pharmaceutically acceptable
- image
- substituted
- Prior art date
Links
- TUSLAEPZELMPGR-UHFFFAOYSA-N 4-piperidin-4-yloxadiazole Chemical class C1CNCCC1C1=CON=N1 TUSLAEPZELMPGR-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012735 Diarrhoea Diseases 0.000 claims abstract 6
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000005561 phenanthryl group Chemical group 0.000 claims 4
- 108090000137 Opioid Receptors Proteins 0.000 claims 3
- 102000003840 Opioid Receptors Human genes 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910006074 SO2NH2 Inorganic materials 0.000 claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940121367 non-opioid analgesics Drugs 0.000 claims 2
- 239000000014 opioid analgesic Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 claims 1
- 239000003793 antidiarrheal agent Substances 0.000 claims 1
- 108700023159 delta Opioid Receptors Proteins 0.000 claims 1
- 102000048124 delta Opioid Receptors Human genes 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims 1
- 102000051367 mu Opioid Receptors Human genes 0.000 claims 1
- 108010020615 nociceptin receptor Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 108020001588 κ-opioid receptors Proteins 0.000 claims 1
- 108020001612 μ-opioid receptors Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Claims (29)
1. Spoj formule (I):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da:
Ar1 je fenil nesupstituiran ili supstituiran sa jednom ili više R2 skupina;
Ar2 je fenil nesupstituiran ili supstituiran sa jednom, dvije ili tri R2 skupine;
Ar4 je fenil nesupstituiran ili supstituiran sa jednom, dvije ili tri R2 skupine;
G je -H, -C(O)(CH2)nCO2R4, -C(O)(CH2)nR5, -(C1-C5 alkilen)C(O)OR4, ili -(C1-C5 alkilen)R5;
R1 = -H, -C(O)NH2, -C(O)NHOH, -CO2R4, -CHO, -CN, -(C1-C4 alkil), -C(O)NH(C1-C4 alkil), -C(O)N(C1-C4 alkil)2, -CF3, -CHF2, -CH2F,
[image]
R2 i R3 su svaki nezavisno -halogen, -C1-C3 alkil, -O(C1-C3 alkil), -NH(C1-C3 alkil), -N(C1-C3 alkil)2, -CF3 ili -OCF3;
R4 = -H, -C1-C10 alkil, -CH2O(C1-C4 alkil), -CH2N(C1-C4 alkil)2, ili -CH2NH(C1-C4 alkil);
R5 = -NH2, -NHSO2R4, -C(O)NH2, -C(O)NHOH, -SO2NH2, -C(O)NH(C1-C4 alkil), -C(O)N(C1-C4 alkil)2, -SO2NH(C1-C4 alkil), -SO2N(C1-C4 alkil)2, -H, -OH, -CN, -C3-C8 cikloalkil, fenil, naftil, antril, fenantril, ili -(5- do 7-člani) heteroaril, svaki -C3-C8 cikloalkil, fenil, naftil, antril, fenantril, ili -(5- do 7-člani) heteroaril je nesupstituiran ili supstituiran sa jednom ili više R2 skupina;
m = cijeli broj u rasponu od 0 do 4;
n = cijeli broj u rasponu od 1 do 4;
p = 0 ili 1; i
q = cijeli broj u rasponu od 1 do 6.
2. Spoj formule (II):
[image]
ili njegova farmaceutski prihvatljiva sol, naznačen time da:
Ar3 je fenil nesupstituiran ili supstituiran sa jednom, dvije ili tri R2 skupine;
Ar4 fenil nesupstituiran ili supstituiran sa jednom, dvije ili tri R2 skupine;
G = -H, -C(O)(CH2)nC(O)OR4, -C(O)(CH2)nR5, -(C1-C5 alkilen)C(O)OR4, ili -(C1-C5 alkilen)R5 ;
R1 = H, -C(O)NH2, -C(O)NHOH, -CO2R4, -CHO, -CN, -(C1-C4 alkil), -C(O)NH(C1-C4 alkil), -C(O)N(C1-C4 alkil)2, -CF3, -CHF2, -CH2F,
[image]
R2 i R3 su svaki nezavisno halogen, -C1-C3 alkil, -O(C1-C3 alkil), -NH(C1-C3 alkil), -N(C1-C3 alkil)2, -CF3, ili -OCF3;
R4 = -H, -C1-C10 alkil, -CH2O(C1-C4 alkil), -CH2N(C1-C4 alkil)2, ili -CH2NH(C1-C4 alkil);
R5 = -NH2, -NHSO2R4, -C(O)NH2, -C(O)NHOH, - SO2NH2, -C(O)NH(C1-C4 alkil), -C(O)N(C1-C4 alkil)2, -SO2NH(C1-C4 alkil), -SO2N(C1-C4 alkil)2, -H, -OH, -CN, -C3-C8 cikloalkil, fenil, naftil, antril, fenantril, ili -(5- do 7-člani) heteroaril, svaki -C3-C8 cikloalkil, fenil, naftil, antril, fenantril, ili -(5- do 7-člani) heteroaril, je nesupstituiran ili supstituiran sa jednom, dvije ili tri R2 skupine;
m = cijeli broj u rasponu od 0 do 4;
n = cijeli broj u rasponu od 1 do 4;
p = 0 ili 1; i
q = cijeli broj u rasponu od 1 do 6.
3. Spoj prema zahtjevu 1 ili 2, naznačen time da m = 1 i G = H.
4. Spoj prema zahtjevu 1 ili 2 naznačen time da R1 je -C(O)NH2, -C(O)NH(C1-C4 alkil), ili -C(O)N(C1-C4 alkil) (C1-C4 alkil).
5. Spoj prema zahtjevu 1 ili 2, naznačen time da R1 je -CN.
6. Spoj prema zahtjevu 1 ili 2, naznačen time da m = 1, p = 0 i q = 3.
7. Spoj prema zahtjevu 1 ili 2, naznačen time da G = -(CH2)2NHSO2H.
8. Spoj prema zahtjevu 1 ili 2, naznačen time da G = -CH2C(O)NH2, -CH2C(O)NH(C1-C4 alkil) ili -CH2C(O)N(C1-C4 alkil) (C1-C4 alkil), poželjno -CH2C(O)NH2.
9. Spoj prema zahtjevu 1 ili 2, naznačen time da G = -CH2C(O)OCH2CH3.
10. Spoj prema zahtjevu 8 ili 9, naznačen time da R1 = -C(O)N(CH3)2.
11. Spoj prema zahtjevu 8 ili 9, naznačen time da R1 je
[image]
.
12. Spoj prema zahtjevu 1 ili 2, naznačen time da G = -(CH2)2C(O)OCH2CH3.
13. Spoj prema zahtjevu 1 ili 2, naznačen time da G = -(CH2)4C(O)OCH2CH3.
14. Spoj prema zahtjevu 1 ili 2, naznačen time da p = 1.
15. Pripravak naznačen time da sadrži spoj prema zahtjevu 1 ili 2 i farmaceutski prihvatljiv nosač ili pomoćnu tvar.
16. Pripravak prema zahtjevu 15, naznačen time da nadalje sadrži barem jedan spoj koji je odabran iz skupine koja sadrži opioidni analgetik, ne-opioidni analgetik, te sredstvo protiv povraćanja.
17. Postupak za dobivanje pripravka, naznačen time da postupak sadrži miješanje spoja prema zahtjevu 1 ili 2 i farmaceutski prihvatljivog nosača ili pomoćne tvari.
18. Kit naznačen time da sadrži spremnik koji sadrži pripravak prema zahtjevu 15, te poželjno dodatno sadrži sredstvo protiv proljeva.
19. Uporaba spoja prema zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli naznačena time da je za dobivanje lijeka za liječenje ili sprečavanje boli ili proljeva.
20. Uporaba prema zahtjevu 19 naznačena time da nadalje sadrži davanje učinkovite količine barem jednog spoja koji je odabran iz skupine koja sadrži opioidni analgetik, ne-opioidni analgetik, te sredstvo protiv povraćanja.
21. Spoj prema zahtjevu 1, naznačen time da je opisan sa slijedećom formulom
[image]
ili njegova farmaceutska sol.
22. Spoj prema zahtjevu 1, naznačen time da je opisan sa slijedećom formulom
[image]
ili njegova farmaceutska sol.
23. Spoj prema zahtjevu 1, naznačen time da je opisan sa slijedećom formulom
[image]
ili njegova farmaceutska sol.
24. Spoj prema zahtjevu 1, naznačen time da je opisan sa slijedećom formulom
[image]
ili njegova farmaceutska sol.
25. Uporaba spoja prema zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli naznačena time da se koristi kao lijek.
26. Uporaba spoja prema zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli naznačena time da je za dobivanje lijeka za stimuliranje funkcije opioidnog-receptora u stanici koje se sastoji od dovođenja u kontakt stanice koja može eksprimirati opioidni receptor sa učinkovitom količinom spoja prema zahtjevu 1 ili 2 ili njegove farmaceutski prihvatljive soli kod liječenja boli ili proljeva.
27. Uporaba prema zahtjevu 26, naznačena time da je receptor odabran iz skupine koja sadrži κ-opioidni receptor, µ-opioidni receptor, δ-opioidni receptor ili ORL-1 receptor za liječenje boli ili proljeva.
28. Spoj prema zahtjevu 1 ili 2 ili njegova farmaceutski prihvatljiva sol naznačen time da je za liječenje boli ili proljeva
29. Spoj prema zahtjevu 1 ili 2 ili njegova farmaceutski prihvatljiva sol naznačen time da je za stimuliranje funkcije opioidnog-receptora u stanici, kod liječenja boli ili proljeva.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73910705P | 2005-11-21 | 2005-11-21 | |
| PCT/EP2006/011150 WO2007057229A1 (en) | 2005-11-21 | 2006-11-21 | 4-oxadiazolyl-piperidine compounds and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20120434T1 HRP20120434T1 (hr) | 2012-06-30 |
| HRP20120434T2 true HRP20120434T2 (hr) | 2012-11-30 |
Family
ID=37898486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120434TT HRP20120434T2 (hr) | 2005-11-21 | 2012-05-23 | Spojevi 4-oksadiazolil-piperidina i njihova uporaba |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20080319020A1 (hr) |
| EP (3) | EP2298764A1 (hr) |
| JP (1) | JP4991746B2 (hr) |
| KR (1) | KR20080080138A (hr) |
| CN (1) | CN101312964A (hr) |
| AT (1) | ATE547414T1 (hr) |
| AU (1) | AU2006314730B2 (hr) |
| BR (1) | BRPI0619679A2 (hr) |
| CA (1) | CA2628750C (hr) |
| CY (1) | CY1112773T1 (hr) |
| DK (1) | DK1951718T3 (hr) |
| EA (1) | EA013510B1 (hr) |
| ES (1) | ES2382712T3 (hr) |
| HR (1) | HRP20120434T2 (hr) |
| NO (1) | NO20082752L (hr) |
| NZ (1) | NZ568430A (hr) |
| PL (1) | PL1951718T3 (hr) |
| PT (1) | PT1951718E (hr) |
| RS (1) | RS52258B (hr) |
| SI (1) | SI1951718T1 (hr) |
| UA (1) | UA91250C2 (hr) |
| WO (1) | WO2007057229A1 (hr) |
| ZA (1) | ZA200803101B (hr) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| BE775611A (fr) | 1970-11-24 | 1972-03-16 | Synthelabo | Derives de la (diphenyl-3,3 propyl-1)-1 piperidine, leur preparation etles medicaments qui en contiennent |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3966748A (en) * | 1975-05-08 | 1976-06-29 | American Cyanamid Company | Para-fluorophenyl-N-heterocyclic substituted butanes |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) * | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5717947A (en) * | 1993-03-31 | 1998-02-10 | Motorola, Inc. | Data processing system and method thereof |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP0833622B8 (en) * | 1995-06-12 | 2005-10-12 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
| US6573282B1 (en) | 1995-09-12 | 2003-06-03 | Adolor Corporation | Peripherally active anti-hyperalgesic opiates |
| US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| CA2324330A1 (en) | 1999-11-08 | 2001-05-08 | Ssp Co., Ltd. | 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same |
| WO2001070689A1 (fr) | 2000-03-24 | 2001-09-27 | Meiji Seika Kaisha, Ltd. | DERIVES DE LA DIPHENYLALKYLAMINE UTILES COMME AGONISTES DU RECEPTEUR DE L'OPIOIDE $g(d) |
| WO2002038185A2 (en) | 2000-11-13 | 2002-05-16 | Atrix Laboratories, Inc. | Injectable sustained release delivery system with loperamide |
| US7202259B2 (en) * | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US20090209578A1 (en) * | 2005-12-08 | 2009-08-20 | Pfizer Inc | Chemical compounds |
| JP2009521531A (ja) * | 2005-12-27 | 2009-06-04 | ザ・ユニバーシティ・オブ・トレド | ムスカリンアゴニスト及びその使用方法 |
-
2006
- 2006-11-21 PT PT06829087T patent/PT1951718E/pt unknown
- 2006-11-21 EA EA200801392A patent/EA013510B1/ru not_active IP Right Cessation
- 2006-11-21 RS RS20120199A patent/RS52258B/en unknown
- 2006-11-21 BR BRPI0619679-9A patent/BRPI0619679A2/pt not_active IP Right Cessation
- 2006-11-21 KR KR1020087015177A patent/KR20080080138A/ko not_active Application Discontinuation
- 2006-11-21 CN CNA2006800432583A patent/CN101312964A/zh active Pending
- 2006-11-21 PL PL06829087T patent/PL1951718T3/pl unknown
- 2006-11-21 SI SI200631317T patent/SI1951718T1/sl unknown
- 2006-11-21 NZ NZ568430A patent/NZ568430A/en not_active IP Right Cessation
- 2006-11-21 EP EP10010919A patent/EP2298764A1/en not_active Withdrawn
- 2006-11-21 CA CA2628750A patent/CA2628750C/en not_active Expired - Fee Related
- 2006-11-21 DK DK06829087.3T patent/DK1951718T3/da active
- 2006-11-21 UA UAA200808315A patent/UA91250C2/ru unknown
- 2006-11-21 WO PCT/EP2006/011150 patent/WO2007057229A1/en active Application Filing
- 2006-11-21 EP EP06829087A patent/EP1951718B9/en active Active
- 2006-11-21 EP EP10010920A patent/EP2298765A1/en not_active Withdrawn
- 2006-11-21 AT AT06829087T patent/ATE547414T1/de active
- 2006-11-21 US US12/094,556 patent/US20080319020A1/en not_active Abandoned
- 2006-11-21 AU AU2006314730A patent/AU2006314730B2/en not_active Ceased
- 2006-11-21 ES ES06829087T patent/ES2382712T3/es active Active
- 2006-11-21 JP JP2008540535A patent/JP4991746B2/ja not_active Expired - Fee Related
-
2008
- 2008-04-09 ZA ZA200803101A patent/ZA200803101B/xx unknown
- 2008-06-18 NO NO20082752A patent/NO20082752L/no not_active Application Discontinuation
-
2012
- 2012-05-18 CY CY20121100458T patent/CY1112773T1/el unknown
- 2012-05-23 HR HRP20120434TT patent/HRP20120434T2/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1951718A1 (en) | 2008-08-06 |
| CA2628750C (en) | 2013-02-12 |
| EP2298764A1 (en) | 2011-03-23 |
| NO20082752L (no) | 2008-08-06 |
| WO2007057229A1 (en) | 2007-05-24 |
| AU2006314730A1 (en) | 2007-05-24 |
| AU2006314730B2 (en) | 2011-02-03 |
| JP2009516664A (ja) | 2009-04-23 |
| PT1951718E (pt) | 2012-05-21 |
| CY1112773T1 (el) | 2016-02-10 |
| CA2628750A1 (en) | 2007-05-24 |
| EP1951718B1 (en) | 2012-02-29 |
| BRPI0619679A2 (pt) | 2011-10-11 |
| ATE547414T1 (de) | 2012-03-15 |
| JP4991746B2 (ja) | 2012-08-01 |
| PL1951718T3 (pl) | 2012-08-31 |
| ES2382712T3 (es) | 2012-06-12 |
| KR20080080138A (ko) | 2008-09-02 |
| DK1951718T3 (da) | 2012-05-14 |
| NZ568430A (en) | 2011-02-25 |
| RS52258B (en) | 2012-10-31 |
| ZA200803101B (en) | 2009-03-25 |
| EA200801392A1 (ru) | 2008-10-30 |
| EP2298765A1 (en) | 2011-03-23 |
| EP1951718B9 (en) | 2012-08-15 |
| HRP20120434T1 (hr) | 2012-06-30 |
| SI1951718T1 (sl) | 2012-06-29 |
| ES2382712T9 (es) | 2012-10-30 |
| CN101312964A (zh) | 2008-11-26 |
| UA91250C2 (en) | 2010-07-12 |
| US20080319020A1 (en) | 2008-12-25 |
| EA013510B1 (ru) | 2010-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2506242A1 (en) | 4-tetrazolyl-4phenylpiperidine derivatives for treating pain | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| ATE12492T1 (de) | Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel. | |
| RU2009102252A (ru) | Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с | |
| AR062793A1 (es) | Compuestos de azetidinona espirociclicos y metodos para su uso | |
| AR036106A1 (es) | Compuestos azaindoles inhibidores de quinasa selectivos, composiciones farmaceuticas y el uso de dicha composicion para la fabricacion de un medicamento | |
| AR054787A1 (es) | Derivados de piperidinas utiles como antagonistas de histamina h3 | |
| EA200900358A1 (ru) | Энантиомерно чистые фосфоиндолы в качестве ингибиторов hiv | |
| RU2011101774A (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| HRP20040178B1 (hr) | Derivati piperidina kao antagonisti nmda receptora | |
| AR054863A1 (es) | DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA | |
| AR016510A1 (es) | Derivados arilalquilaminicos calciliticos, una composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de unmedicamento | |
| RU2011103234A (ru) | Новые фенилпиразиноны в качестве ингибиторов киназы | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| RU2009146124A (ru) | Дигидрохиноновые и дигидронафтиридиновые ингибиторы киназы jnk | |
| RU2009124304A (ru) | Производные азабициклооктана, способ их получения и их применения в качестве ингибиторов дипептидилпептидазы iv | |
| RU2017126128A (ru) | Конденсированные бициклические соединения для лечения заболевания | |
| RU2010101611A (ru) | Полициклические производные гуанина и способы их применения | |
| GB1046506A (en) | Guanidine compounds and process for their manufacture | |
| RU2007122406A (ru) | Производные тетралина и индана и их применения в качестве антагонистов 5-нт | |
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| JP2015502371A5 (hr) | ||
| JP2005520864A5 (hr) | ||
| EA201070603A1 (ru) | Лекарственное средство, активное в отношении невропатической боли |